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 Abstract 
 Background: TDP-43 is the main protein component of ubiquitinated inclusions in a sub-
group of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) 
patients. The  C9ORF72 hexanucleotide expansion is one of the main mutations associated 
with TDP-43 pathology in FTLD and ALS. Our aim was to analyze cerebrospinal fluid (CSF) 
TDP-43 levels and Alzheimer’s disease biomarkers in FTLD and ALS patients and to test wheth-
er the  C9ORF72 expansion carrier status affects these variables.  Methods: The patient cohort 
consisted of 90 clinically well-characterized FTLD (n = 69) and ALS (n = 21) patients. There 
were 30 patients with the  C9ORF72 expansion and 60 patients without the expansion. CSF 
TDP-43, Aβ 1–42 , t-tau, and phospho-tau levels were measured using commercial ELISA kits. 
 Results: There was no difference in CSF TDP-43 levels between the  C9ORF72 expansion car-
riers and the noncarriers. CSF TDP-43 levels were higher in ALS patients than in FTLD patients, 
and this finding was independent of the  C9ORF72 expansion carrier status. Males had sig-
nificantly higher TDP-43 levels than females (p = 0.008 in the total cohort).  Conclusion: CSF 
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TDP-43 does not seem to distinguish the  C9ORF72 expansion carriers from noncarriers. How-
ever, higher CSF TDP-43 levels were detected in ALS than in FTLD, which might be an indicator 
of a more rapid progression of TDP-43 pathology in ALS.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Frontotemporal lobar degeneration (FTLD) is a genetically and neuropathologically 
heterogeneous group of syndromes. There are three clinically recognized subtypes: behav-
ioral-variant frontotemporal dementia (FTD) with predominant behavioral and executive 
problems, and two language variants, namely progressive nonfluent aphasia and semantic 
dementia  [1] . Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder where the 
loss of motor neurons causes progressive weakness, fasciculations, and muscle atrophy. 
FTLD and ALS are overlapping syndromes, and about 15% of the patients with FTLD also 
develop concomitant ALS (FTLD-ALS)  [2] . ALS patients may also show signs of cognitive 
impairment, usually a type of behavioral-variant FTD  [3] . 
 The molecular pathologies of FTLD and ALS show many similar pathological features. 
FTLD can be divided into five subtypes of which the two main differential pathological char-
acteristics are FTLD-TDP (TDP-43 and ubiquitin-positive, tau-negative inclusions) and 
FTLD-tau (tau-positive inclusions)  [4] . ALS is mainly associated with TDP-43 pathology, 
while tau pathology is not typical in ALS. The TDP-43 protein is normally expressed in many 
tissues, including the brain, and it has been identified as the major component of ubiquitin-
positive inclusions in the brain of FTLD patients (as shown in our own series of autopsy cases) 
and ALS patients  [5] . It is localized in the nucleus or shifts between the nucleus and the cyto-
plasm  [6–8] . TDP-43 proteinopathies are characterized by insoluble neuronal cytoplasmic or 
intranuclear inclusions and glial cytoplasmic inclusions, which aggregate in the cells  [9] . Cell 
death results in the release of TDP-43 and, therefore, the TDP-43 levels in cerebrospinal fluid 
(CSF) may increase.
 There have only been a few previous reports on TDP-43 levels in FTLD and ALS patients 
with a known genetic background. Since the  C9ORF72 expansion is one of the most common 
genetic causes of FTLD and ALS with a TDP-43 pathology  [10, 11] and is especially common 
in Finland  [12] , our aim was to improve the panel of possible biomarkers in the differential 
diagnostic process of FTLD, and we hypothesized that the  C9ORF72 expansion may have an 
effect on CSF TDP-43 levels. Furthermore, we have previously demonstrated that changes in 
CSF Alzheimer’s disease (AD) biomarker levels (Aβ 1–42 , t-tau, and phospho-tau) can be 
observed in patients carrying the  C9ORF72 expansion  [13] . In this study, we investigated the 
CSF TDP-43 as well as the CSF AD biomarker levels in clinically well-characterized FTLD and 
ALS patients, including both  C9ORF72 expansion carriers and noncarriers. 
 Materials and Methods 
 Subjects and Samples 
 The patient cohort consisted of 90 clinically well-characterized FTLD (n = 69; 29 males) 
and ALS (n = 21; 10 males) patients, of whom 30 were  C9ORF72 expansion carriers and 60 
were noncarriers ( table 1 ). 
 The  C9ORF72 expansion (>45 repeats) was detected using a repeat-primed PCR  [11] . 
 APOE genotyping was done using a PCR-based method with the forward PCR primer 5 ′ -GCA 
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CGG CTG TCC AAG GAG CTG CAG GC-3 ′ and the reverse PCR primer 5 ′ -GGC GCT CGC GGA TGG 
CGC TGA G-3 ′  [14] . The CSF samples were obtained by lumbar puncture during the diagnostic 
procedure and stored in polypropylene tubes at –70  °  C until the analysis. The study was 
approved by the ethics committees of the Kuopio and Oulu University Hospitals and followed 
the principles of the Declaration of Helsinki. All patients agreed to participate in the study, 
and blood and CSF samples were obtained after receiving written informed consent from 
patients and/or their legal representatives.
 Measurements 
 The CSF TDP-43 levels were measured using a commercial ELISA (Cusabio, PR China) 
according to the manufacturer’s protocol. The kit was tested first by measuring CSF samples 
not intended for this study, and there was a notable drift in the values measured. The beginning 
of the plate gave significantly higher values than the end of the plate. Therefore, the analyses 
were done by using half of the plate in each run, and the drift was acceptable. All samples were 
measured in triplicates. The CSF Aβ 1–42 , t-tau, and phospho-tau levels were measured using 
a commercial ELISA (Innogenetics, Ghent, Belgium) according to the manufacturer’s protocol. 
Samples were measured in duplicates, and the results were analyzed blind to diagnosis. 
 Statistical Analyses 
 Statistical analyses were performed using SPSS 21. Statistical significance was set at p < 
0.05. The test of normality was done using the Kolmogorov-Smirnov test and the Shapiro-
Wilk test. Statistical analyses were performed using a t test, the Mann-Whitney test, and the 
χ 2 test. Correlations were analyzed using Pearson’s correlation test. All results are given as 
means ± SD, unless otherwise stated. 
 Results 
 The mean CSF TDP-43 level was 3.2 ± 1.2 pg/ml in the total cohort ( table 1 ). There was 
no statistically significant difference in the mean CSF TDP-43 levels between the  C9ORF72 
expansion carriers and noncarriers in different diagnostic groups ( tables 2 ,  3 ;  fig. 1 a, b). 
Female patients had lower CSF TDP-43 levels than male patients in the total cohort (2.9 ± 0.9 
vs. 3.6 ± 1.4 pg/ml in females vs. males, respectively; p = 0.008), in the FTLD subcohort 
(2.7 ± 0.8 vs. 3.3 ± 1.2 pg/ml in females vs. males, respectively; p = 0.029), and in the ALS 
 Table 1.  Clinical characteristics of the patients
FTLD patients ALS patients Total patients p value
Subjects 69 (76.7) 21 (23.3) 90
Age, years 65.8 ± 9.7 61.9 ± 8.0 64.9 ± 9.4 0.961
Male/female 29/40 (42/58) 10/11 (47.6/52.4) 39/51 (43.3/56.7) 0.008
MMSE
Missing cases, n
22.1 ± 5.2
7
23.2 ± 3.9
15
22.2 ± 5.1
22
0.326
APOE allele frequency ε2/3/4
Missing cases, n
0.06/0.70/0.24
20
0.06/0.76/0.18
4
0.06/0.72/0.22
24
0.260
CSF TDP-43, pg/ml 3.0 ± 1.0 4.1 ± 1.3 3.2 ± 1.2 0.001
CSF Aβ1 – 42, pg/ml 647.7 ± 244.9 762.9 ± 302.2 674.6 ± 262.2 0.134
CSF t-tau, pg/ml 362.7 ± 269.7 315.4 ± 124.3 351.7 ± 243.9 0.910
CSF phospho-tau, pg/ml 64.8 ± 35.3 48.4 ± 14.2 61.0 ± 32.3 0.147
 Values are presented as n (%) or means ± SD unless otherwise specified.
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subcohort (3.6 ± 0.9 vs. 4.7 ± 1.6 pg/ml in females vs. males, respectively; p = 0.069). There 
was no correlation between the CSF TDP-43 levels and the Mini-Mental State Examination 
(MMSE), age, or  APOE  ε4 carrier or noncarrier status in the total cohort or in different clinical 
phenotypes. 
 Interestingly, we found that the CSF TDP-43 levels were significantly higher in ALS 
patients than in FTLD patients in the total cohort (p = 0.001;  tables 1–3 ). A similar significant 
difference between the two diagnostic groups in the mean CSF TDP-43 levels was also found 
in patients with the  C9ORF72 expansion (p = 0.003).
 In the total cohort, there were abnormal CSF Aβ 1–42 levels in 20%, abnormal CSF t-tau 
levels in 22%, and abnormal CSF phospho-tau levels in 24% of patients. The portions of 
abnormal biomarker levels in the subgroups are shown in  table 4 . All 3 AD biomarkers were 
abnormal in only 3  C9ORF72 expansion noncarrier FTLD patients (4%). Furthermore, 16 
FTLD patients (23%) had 1 abnormal biomarker, and 12 patients (17%) had 2 abnormal 
biomarkers. In the ALS group, 5 patients (24%) had 1 abnormal biomarker, and 3 patients 
 Table 2. Clinical characteristics of the FTLD patients
FTLD patients,
C9ORF72 expansion 
positive
FTLD patients,
C9ORF72 expansion 
negative
Total patients p value
Subjects 20 (29.0) 49 (71.0) 69
Age, years 63.3 ± 8.4 61.9 ± 8.0 65.8 ± 9.7 0.915
Male/female 7/13 (35/65) 22/27 (44.9/55.1) 29/40 (42/58) 0.029
MMSE
Missing cases, n
24.9 ± 3.2
3
21.0 ± 5.5
4
22.1 ± 5.2
7
0.140
APOE allele frequency ε2/3/4
Missing cases, n
0.05/0.82/0.13
1
0.07/0.63/0.30
19
0.06/0.70/0.24
20
0.0124
CSF TDP-43, pg/ml 2.9 ± 0.7 3.0 ± 1.1 3.0 ± 1.0 0.786
CSF Aβ1 – 42, pg/ml 649.8 ± 243.2 646.8 ± 248.1 647.7 ± 244.9 0.716
CSF t-tau, pg/ml 262.0 ± 105.5 403.9 ± 304.5 362.7 ± 269.7 0.871
CSF phospho-tau, pg/ml 47.6 ± 14.1 71.8 ± 38.9 64.8 ± 35.3 0.548
Values are presented as n (%) or means ± SD unless otherwise specified.
 Table 3. Clinical characteristics of the ALS patients
ALS patients,
C9ORF72 expansion 
positive
ALS patients,
C9ORF72 expansion 
negative
Total patients p value
Subjects 10 (47.6) 11 (52.4) 21
Age, years 58.6 ± 6.5 64.9 ± 8.3 61.9 ± 8.0 0.117
Male/female 4/6 (40/60) 6/5 (54.5/45.5) 10/11 (47.6/52.4) 0.069
MMSE
Missing cases, n
29.0
9
22.0 ± 2.9
6
23.2 ± 3.9
15
0.199
APOE allele frequency ε2/3/4
Missing cases, n
0.06/0.81/0.12
2
0.06/0.72/0.22
2
0.06/0.76/0.18
4
0.407
CSF TDP-43, pg/ml 4.6 ± 1.5 3.7 ± 1.0 4.1 ± 1.3 0.116
CSF Aβ1 – 42, pg/ml 794.1 ± 283.6 734.6 ± 329.2 762.9 ± 302.2 0.425
CSF t-tau, pg/ml 260.1 ± 147.6 365.7 ± 73.9 315.4 ± 124.3 0.215
CSF phospho-tau, pg/ml 39.3 ± 7.8 56.6 ± 13.9 48.4 ± 14.2 0.642
Values are presented as n (%) or means ± SD unless otherwise specified.
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(14%) had 2 abnormal biomarkers. There were no differences in the CSF Aβ 1–42 , t-tau, and 
phospho-tau levels between the  C9ORF72 expansion carriers and noncarriers or the diag-
nostic subgroups. The CSF TDP-43 levels did not correlate with the CSF Aβ 1–42 , t-tau, or 
phospho-tau levels in the total cohort nor in any subgroup either.
 Discussion 
 Contrary to our hypothesis, we did not find any significant differences in the CSF TDP-43 
levels between the  C9ORF72 expansion carriers and noncarriers. There is only one previous 
study concerning the CSF TDP-43 levels in genetically determined FTD patients (n = 25)  [15] . 
However, there were only 2  C9ORF72 expansion and 3 progranulin mutation carriers in that 
cohort; the 3 mutation carriers had higher CSF TDP-43 levels than the remaining FTD patients 
without known mutations. Our analysis in a larger sample (30  C9ORF72  carriers vs. 60 noncar-
riers) does not support the previous finding. The contradictory findings may be due to a 
sample size that is still too small or the different methodology used to analyze the CSF TDP-43 
levels. 
 We found that CSF TDP-43 was higher in patients with ALS than in patients with FTLD in 
the total cohort, and this phenotype-dependent correlation was also found in patients with 
the  C9ORF72 expansion. Similar findings concerning increased CSF TDP-43 levels in patients 
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 Fig. 1.  a CSF TDP-43 levels in FTLD and ALS patients.  b Different diagnostic groups and  C9ORF72  (ORF) ex-
pansion status. The mean levels are marked by lines. 
 Table 4. Abnormal CSF AD biomarker level portions in the total cohort and in the subcohorts
Total
cohort
FTLD 
patients
(n =69)
FTLD
C9ORF72
carriers 
(n = 20)
FTLD
C9ORF72 
noncarriers 
(n = 49)
ALS 
patients
(n = 21)
ALS
C9ORF72
carriers 
(n = 10)
ALS
C9ORF72
noncarriers
CSF Aβ1 – 42 20% 22% 20% 22% 14% 30% 0%
CSF t-tau 22% 22% 5% 29% 24% 10% 36%
CSF phospho-tau 24% 28% 25% 29% 14% 0% 27%
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with ALS compared to healthy controls have been found in a few previous studies  [16–18] . 
One of these studies also included FTLD patients, and elevated CSF TDP-43 levels were also 
detected in this phenotype, while there was no difference between FTLD and ALS patients 
when using the immunoblot method  [16] . The examined cohort was rather large (n = 39), but 
there was no information on the genetic background. 
 The reason for the higher CSF TDP-43 levels in ALS patients may be the faster neurode-
generation and disease progression in this patient group. The survival time after the diag-
nosis of ALS is usually 3–4 years, whereas FTLD patients may have a survival time of more 
than 10 years. The more rapid neurodegeneration in ALS may release intracellular TDP-43 
from inclusions, which may lead to elevated TDP-43 levels in the CSF compared to FTLD. 
According to this hypothesis, CSF TDP-43 levels would be higher in patients with a more rapid 
progression of the disease. In the present study, survival data are not yet available, and it has 
to be noted that opposite results have also been presented. Noto et al.  [18] found that, in 
patients with ALS, the highest levels of TDP-43 were detected in cases with a slower 
progression of the disease.
 The origin of TDP-43 in the CSF has also been speculated on. In a small cohort (n = 13) of 
FTLD and ALS patients without known genetic background, Feneberg et al.  [19] studied the 
levels of TDP-43 in the CSF, lymphocytes, and serum by one- and two-dimensional Western 
blotting and quantitative mass spectrometry. They found, surprisingly, that the TDP-43 in the 
CSF mainly originated from blood and, thus, CSF or blood TDP-43 levels may not be a useful 
diagnostic tool. 
 We found that CSF TDP-43 levels were higher in men in the total cohort and in both the 
FTLD and the ALS subcohorts. In previous studies, no differences in the TDP-43 levels between 
men and women have been detected. The incidence and prevalence of ALS is higher in men 
than in women. The onset of the disease is also earlier in men, but differences in survival time 
have not been detected  [20] . The reason for these differences is unknown, but they may be 
due to differences between the male and female nervous system and differences in the ability 
to repair damage  [20] . According to this notion, it is possible that the differences in the TDP-43 
levels of men and women are caused by gender-specific differences in the nervous system and 
in the ability to process TDP-43. 
 In our previous study, we investigated CSF AD biomarker levels (Aβ 1–42 , t-tau, and 
phospho-tau) in patients with the  C9ORF72 expansion, and we found decreased CSF Aβ 1–42 
levels in 25% of the cases  [13] . A similar profile of AD biomarkers in patients with the  C9ORF72 
 expansion was found in the present study in both clinical phenotypes (FTLD and ALS). 
Changes in t-tau and phospho-tau were also detected in a significant proportion of patients 
with and without the  C9ORF72 expansion. However, there was no difference in the CSF AD 
biomarker levels between  C9ORF72 expansion carriers and noncarriers in the different diag-
nostic groups. A relatively high number of FTLD patients without the  C9ORF72 expansion may 
represent mixed or tau-pathology, which may have been reflected in the elevation of CSF t-tau 
and phospho-tau levels  [21, 22] . 
 There was no correlation between the  APOE genotype and the CSF TDP-43 level. In the 
present study, the frequency of APOE  ε4 was higher in  C9ORF72 expansion noncarriers than 
in carriers. However, the frequency of  APOE  ε4  in the noncarriers is the same as in the general 
Finnish population  [23] . Interestingly, the frequency of APOE  ε4 in the FTLD patients with the 
 C9ORF72 expansion was remarkably low. 
 In conclusion, CSF TDP-43 levels seem to be associated with ALS and may be a marker of 
more rapid progression of diseases presenting with TDP-43 pathology. However, CSF TDP-43 
does not seem to distinguish  C9ORF72 expansion carriers from noncarriers. 
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